Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

MEN2A-RET-induced cellular transformation by activation of STAT3.

Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R, Kruijer W.

Oncogene. 2001 Aug 30;20(38):5350-8.

2.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

3.

Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.

Kato M, Takeda K, Kawamoto Y, Iwashita T, Akhand AA, Senga T, Yamamoto M, Sobue G, Hamaguchi M, Takahashi M, Nakashima I.

Cancer Res. 2002 Apr 15;62(8):2414-22.

4.

Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.

Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M.

Oncogene. 1996 Feb 1;12(3):481-7.

PMID:
8637703
5.

Role of Dok1 in cell signaling mediated by RET tyrosine kinase.

Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K, Takahashi M.

J Biol Chem. 2002 Sep 6;277(36):32781-90.

6.

Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.

Qiao S, Iwashita T, Furukawa T, Yamamoto M, Sobue G, Takahashi M.

J Biol Chem. 2001 Mar 23;276(12):9460-7.

7.

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.

Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH, et al.

Science. 1995 Jan 20;267(5196):381-3.

PMID:
7824936
8.
9.

RET activation by germline MEN2A and MEN2B mutations.

Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, Lorenzo MJ, Arighi E, Miranda C, Eng C, Alberti L, et al.

Oncogene. 1995 Dec 7;11(11):2419-27.

PMID:
8570194
10.

Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.

Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M.

Cancer Res. 2001 Feb 15;61(4):1426-31.

11.

Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation.

Hayashi Y, Iwashita T, Murakamai H, Kato Y, Kawai K, Kurokawa K, Tohnai I, Ueda M, Takahashi M.

Biochem Biophys Res Commun. 2001 Mar 2;281(3):682-9.

PMID:
11237712
12.

RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.

Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM.

Cancer Res. 2005 Mar 1;65(5):1729-37.

13.

Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.

Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M.

Biochem Biophys Res Commun. 1997 Aug 28;237(3):747-51.

PMID:
9299438
14.

Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.

De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN, Santoro M.

Cancer Res. 2000 Jul 15;60(14):3727-31.

15.
16.

Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation.

Shi CS, Kehrl JH.

J Biol Chem. 2004 Apr 23;279(17):17224-31.

17.

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.

Asai N, Iwashita T, Matsuyama M, Takahashi M.

Mol Cell Biol. 1995 Mar;15(3):1613-9.

18.

Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.

Bongarzone I, Vigano E, Alberti L, Borrello MG, Pasini B, Greco A, Mondellini P, Smith DP, Ponder BA, Romeo G, Pierotti MA.

Oncogene. 1998 May 7;16(18):2295-301.

19.

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.

Chappuis-Flament S, Pasini A, De Vita G, Ségouffin-Cariou C, Fusco A, Attié T, Lenoir GM, Santoro M, Billaud M.

Oncogene. 1998 Dec 3;17(22):2851-61.

20.

Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.

Hwang ES, Kim DW, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M.

Mol Endocrinol. 2004 Nov;18(11):2672-84.

PMID:
15297606
Items per page

Supplemental Content

Support Center